JMT-108

N/A

Report date: 2026/01/23 17:10:38

Base Information

Drug NameJMT-108
Drug Alias NameJMT108JMT-108
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAnti-PD-1Interleukin-15 modulators
TargetsProgrammed cell death protein 1Interleukin-15
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Jmt-Bio Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesConjupro Biotherapeutics IncShanghai Jmt-Bio Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A